HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd.

Researchers at Baylor College of Medicine have discovered a potential new strategy to fight back against Alzheimer's and ...

Summary: Women make up nearly two-thirds of Alzheimer’s patients, and researcher may have just discovered a massive reason why. A new study found that when the protein alpha-synuclein (typically ...

Tubulin acts as a master regulator, preventing Tau and alpha-synuclein from forming toxic clumps in Alzheimer's and Parkinson's.

Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program -- First-in-kind technology ...

Webcast: Link will be posted on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events ...

- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and ...

JERUSALEM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, ...

Following an incredibly productive 2025, culminating in several significant announcements in recent weeks, I wish to share with you an updated comprehensive picture of Alpha Tau’s position and ...

JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital ...

Key proteins implicated in neurodegenerative diseases are alpha synuclein and tau. Tau aggregation into neurofibrillary tangles, along with amyloid-beta aggregation into plaques, is a hallmark of ...